NEWYou can now listen to Fox News articles!
AstraZeneca announced on Mondaytwo existing therapies to boost its oncology portfolio in the treatment of certain high-risk breast cancer patients in the European Union. Said that was recommended.
Lymphalza, an anticancer drug developed in collaboration with US-based Merck, can be used alone or with endocrine therapy in adults with genetically mutated forms of early-stage breast cancer. Assisted for the combination.
A drug that received similar recommendations in the United States in Marchis an important asset of AstraZeneca. It was recommended for patients with low to normal levels of a protein known as HER2, which is the target of several new therapies.
AstraZeneca buys Alexion for $ 39 billion to expand immunology
The AstraZeneca logo was seen outside the North American headquarters in Wilmington, Delaware, USA, March 22, 2021. increase.( REUTERS / Rachel Wisnievsky / File photo)
The Enhertz co-developed with Daiichi Sankyo in Japan isBreast cancer characterized by a high proportion of HER2.
AstraZeneca wins $ 4 billion in COVID-19 vaccine sales
Enhertu is considered a major growth driver for AstraZeneca And some analysts expect a peak in sales of $ 10 billion. Following the success of a recent trial, the drug is expected to be cleared in patients with low HER2 levels this month.